Tybost - Gilead Sciences, Inc.
... with other antiretroviral agents in the treatment of HIV-1 infection. (1) Limitations of Use: TYBOST is not interchangeable with ritonavir to increase systemic exposure of darunavir 600 mg twice daily, fosamprenavir, saquinavir, or tipranavir due to lack of exposure data. The use of TYBOST is not ...
... with other antiretroviral agents in the treatment of HIV-1 infection. (1) Limitations of Use: TYBOST is not interchangeable with ritonavir to increase systemic exposure of darunavir 600 mg twice daily, fosamprenavir, saquinavir, or tipranavir due to lack of exposure data. The use of TYBOST is not ...
sinemet cr - Merck.com
... Carbidopa inhibits decarboxylation of peripheral levodopa. It does not cross the blood-brain barrier and does not affect the metabolism of levodopa within the central nervous system. Since its decarboxylase inhibiting activity is limited to extracerebral tissues, administration of carbidopa with lev ...
... Carbidopa inhibits decarboxylation of peripheral levodopa. It does not cross the blood-brain barrier and does not affect the metabolism of levodopa within the central nervous system. Since its decarboxylase inhibiting activity is limited to extracerebral tissues, administration of carbidopa with lev ...
Concomitant Administration of Clopidogrel With Statins or Calcium
... Dr. Wiviott is a consultant for Angelmed, Eisai, Aegerion, Janssen Pharmaceuticals, St. Jude Medical, and Xoma; and has received research funding from Merck & Co., Eisai, AstraZeneca, and Eli Lilly and Company/Daichi Sankyo. Dr. Antman has received research funding from Eli Lilly and Company and Dai ...
... Dr. Wiviott is a consultant for Angelmed, Eisai, Aegerion, Janssen Pharmaceuticals, St. Jude Medical, and Xoma; and has received research funding from Merck & Co., Eisai, AstraZeneca, and Eli Lilly and Company/Daichi Sankyo. Dr. Antman has received research funding from Eli Lilly and Company and Dai ...
PERCOCET
... acetaminophen containing product. The excessive intake of acetaminophen may be intentional to cause self-harm or unintentional as patients attempt to obtain more pain relief or unknowingly take other acetaminophen-containing products. The risk of acute liver failure is higher in individuals with und ...
... acetaminophen containing product. The excessive intake of acetaminophen may be intentional to cause self-harm or unintentional as patients attempt to obtain more pain relief or unknowingly take other acetaminophen-containing products. The risk of acute liver failure is higher in individuals with und ...
... had to be within 15% of that on test day 1. A highly significant difference was found between the predose FEV1 on the first test day and that on subsequent test days (p=0.001). Moreover, there appeared to be a significant effect from the treatment at the previous visit on the predose FEV1 of the sub ...
atorvastatin - Clinical Trial Results
... LIPITOR® 10 mg (n=73), 20 mg (n=51), 40 mg (n=61), 80 mg (n=10); simvastatin 10 mg (n=70), 20 mg (n=49), 40 mg (n=61); pravastatin 10 mg (n=14), 20 mg (n=41), 40 mg (n=25); lovastatin 20 mg (n=16), 40 mg (n=16), 80 mg (n=11); fluvastatin 20 mg (n=12), 40 mg (n=12). Baseline LDL-C values were similar ...
... LIPITOR® 10 mg (n=73), 20 mg (n=51), 40 mg (n=61), 80 mg (n=10); simvastatin 10 mg (n=70), 20 mg (n=49), 40 mg (n=61); pravastatin 10 mg (n=14), 20 mg (n=41), 40 mg (n=25); lovastatin 20 mg (n=16), 40 mg (n=16), 80 mg (n=11); fluvastatin 20 mg (n=12), 40 mg (n=12). Baseline LDL-C values were similar ...
Prescribing Information - PI
... cardiovascular effect in some patients as measured by increases in pulse rate, systolic or diastolic blood pressure, or symptoms [see Clinical Pharmacology (12.2)]. If such effects occur, BEVESPI AEROSPHERE may need to be discontinued. In addition, beta-agonists have been reported to produce electro ...
... cardiovascular effect in some patients as measured by increases in pulse rate, systolic or diastolic blood pressure, or symptoms [see Clinical Pharmacology (12.2)]. If such effects occur, BEVESPI AEROSPHERE may need to be discontinued. In addition, beta-agonists have been reported to produce electro ...
Pocket Guide - Cancer Care Ontario
... Potentially all dopamine antagonists can cause EPS, to varying degrees, due to the D2 central antagonist actions. Manifestations of EPS are usually dose dependent. Extrapyramidal side effects may include: acute dystonia, akathisia, and Parkinson-like signs/symptoms. Akathisia and acute dyston ...
... Potentially all dopamine antagonists can cause EPS, to varying degrees, due to the D2 central antagonist actions. Manifestations of EPS are usually dose dependent. Extrapyramidal side effects may include: acute dystonia, akathisia, and Parkinson-like signs/symptoms. Akathisia and acute dyston ...
Extract from Clinical Evaluation Report: Fentanyl citrate
... Comment: The potential advantages of Abstral are acknowledged. On the other hand, one of the advantages of Actiq – particularly during initial dose titration – is that the product can be removed from the mouth if signs of excessive opioid effects appear. This is less feasible with a rapidly-disinteg ...
... Comment: The potential advantages of Abstral are acknowledged. On the other hand, one of the advantages of Actiq – particularly during initial dose titration – is that the product can be removed from the mouth if signs of excessive opioid effects appear. This is less feasible with a rapidly-disinteg ...
urticaria
... It would seem that the combination of H1 and H2 antihistamines would provide optimal effects. The results of studies are conflicting but generally show that the combination is only slightly more effective than an H1-blocking agent used alone. ...
... It would seem that the combination of H1 and H2 antihistamines would provide optimal effects. The results of studies are conflicting but generally show that the combination is only slightly more effective than an H1-blocking agent used alone. ...
rational use of diuretics and pathophysiology of edema
... advisable to combine substances with different half-lives of action. In the particular case of loop diuretics (short half-life) and thiazides (long half-life) this approach may, however, have distinct advantages. First, co-administration of thiazide and loop diuretics may help to overcome “resistanc ...
... advisable to combine substances with different half-lives of action. In the particular case of loop diuretics (short half-life) and thiazides (long half-life) this approach may, however, have distinct advantages. First, co-administration of thiazide and loop diuretics may help to overcome “resistanc ...
Ibavyr Datasheet 200, 400, 600mg
... triazole carboxylic acid metabolites is renal (accounting for about 5 – 15% of single dose elimination), with the majority of the dose eliminated as metabolites rather than as parent compound. Due to extensive distribution, the terminal half-life of a single oral dose is around 120 to 170 hours and ...
... triazole carboxylic acid metabolites is renal (accounting for about 5 – 15% of single dose elimination), with the majority of the dose eliminated as metabolites rather than as parent compound. Due to extensive distribution, the terminal half-life of a single oral dose is around 120 to 170 hours and ...
Coma after levetiracetam overdose
... hours and about 93% of the drug is excreted within 48 hours after oral administration. Levetiracetam metabolism is not dependent on the hepatic CYP.4 The recommended dosing is to start with 1000 mg/day increasing stepwise to a maximum recommended dose of 3000 mg daily5 and therapeutic serum concentr ...
... hours and about 93% of the drug is excreted within 48 hours after oral administration. Levetiracetam metabolism is not dependent on the hepatic CYP.4 The recommended dosing is to start with 1000 mg/day increasing stepwise to a maximum recommended dose of 3000 mg daily5 and therapeutic serum concentr ...
DRUG NAME: Hydroxyurea
... 9. Rose BD editor. Hydroxyurea: Pediatric drug information. UpToDate 14.2 ed. Waltham, Massachusetts: UpToDate®; 2006. 10. BC Cancer Agency. (SCNAUSEA) Guidelines for Prevention and Treatment of Chemotherapy-induced Nausea and Vomiting in ...
... 9. Rose BD editor. Hydroxyurea: Pediatric drug information. UpToDate 14.2 ed. Waltham, Massachusetts: UpToDate®; 2006. 10. BC Cancer Agency. (SCNAUSEA) Guidelines for Prevention and Treatment of Chemotherapy-induced Nausea and Vomiting in ...
Peridex and PerioMed Oral Rinse Brochure
... inflammation following treatment with Peridex oral rinse should not be used as a major indicator of underlying periodontitis. 2. Peridex oral rinse can cause staining of oral surfaces, such as tooth surfaces, restorations, and the dorsum of the tongue. Not all patients will experience a visu ...
... inflammation following treatment with Peridex oral rinse should not be used as a major indicator of underlying periodontitis. 2. Peridex oral rinse can cause staining of oral surfaces, such as tooth surfaces, restorations, and the dorsum of the tongue. Not all patients will experience a visu ...
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1
... not take the missed dose. Patients should not take a double dose (two doses at the same time) to make up for a forgotten dose. Paediatric population The safety and efficacy of IRESSA in children and adolescents aged less than 18 years have not been established. There is no relevant use of gefitinib ...
... not take the missed dose. Patients should not take a double dose (two doses at the same time) to make up for a forgotten dose. Paediatric population The safety and efficacy of IRESSA in children and adolescents aged less than 18 years have not been established. There is no relevant use of gefitinib ...
Recalcitrant and Recurrent Candidiasis and Bacterial Vaginosis
... given in the physician’s office as a 1.0% solution (once weekly for up to three times). Permanent purple staining on clothing may occur. Some patients develop a vulvar irritation following application. 5-flucytosine This is a pyrimidine developed for use as an anticancer drug. Though not effective a ...
... given in the physician’s office as a 1.0% solution (once weekly for up to three times). Permanent purple staining on clothing may occur. Some patients develop a vulvar irritation following application. 5-flucytosine This is a pyrimidine developed for use as an anticancer drug. Though not effective a ...
Clinical pearls
... Decrease dose by 10-25%; recheck in 3 days and q 6-12 months Hold one dose; decrease maintenance dose by 25%; recheck in 3 days and q 6-12 months Hold two doses; decrease maintenance dose by 50%; recheck to guide dosage adjustment; consider activated charcoal for toxicity ...
... Decrease dose by 10-25%; recheck in 3 days and q 6-12 months Hold one dose; decrease maintenance dose by 25%; recheck in 3 days and q 6-12 months Hold two doses; decrease maintenance dose by 50%; recheck to guide dosage adjustment; consider activated charcoal for toxicity ...
Advicor® (niacin extended-release/lovastatin tablets)
... after oral administration is low (<5%) and shows considerable inter-individual variation. Peak concentrations of active and total inhibitors occur within 2 to 4 hours after Mevacor® administration. ...
... after oral administration is low (<5%) and shows considerable inter-individual variation. Peak concentrations of active and total inhibitors occur within 2 to 4 hours after Mevacor® administration. ...
PRODUCT INFORMATION - Medicines Information
... lumen diameters (co-primary endpoints, indicating focal and diffuse disease, respectively), as well as in percent diameter stenosis (p=0.003). Simvastatin also significantly decreased the proportion of patients with new lesions (13% simvastatin vs 24% placebo, p=0.009) and with new total occlusions ...
... lumen diameters (co-primary endpoints, indicating focal and diffuse disease, respectively), as well as in percent diameter stenosis (p=0.003). Simvastatin also significantly decreased the proportion of patients with new lesions (13% simvastatin vs 24% placebo, p=0.009) and with new total occlusions ...
Update in 2015: Novel Oral Anticoagulant (NOAC
... would be in a non-‐critical location and controllable. Discontinue the NOAC at least 48 hours prior to surgery with a moderate or high risk of bleeding. Some interventions may require longer holds ...
... would be in a non-‐critical location and controllable. Discontinue the NOAC at least 48 hours prior to surgery with a moderate or high risk of bleeding. Some interventions may require longer holds ...
Current treatment of oral candidiasis: A literature review
... also correct the predisposing factors and underlying diseases and try to promote the use of oral antiseptic and antibacterial rinses such as Chlorhexidine or Hexetidine (12). These measures are very effective in patients with denture stomatitis (12). It was also found in the study of Cross et al. (1 ...
... also correct the predisposing factors and underlying diseases and try to promote the use of oral antiseptic and antibacterial rinses such as Chlorhexidine or Hexetidine (12). These measures are very effective in patients with denture stomatitis (12). It was also found in the study of Cross et al. (1 ...
$doc.title
... Since diabetes is frequently complicated by renal disease, a lower starting dose and gradual increase in dose should be considered for patients with renal impairment [see Clinical Pharmacology (12.3) and Dosage and Administration (2.3)]. Fibromyalgia — The recommended dose for Cymbalta is 60 mg admi ...
... Since diabetes is frequently complicated by renal disease, a lower starting dose and gradual increase in dose should be considered for patients with renal impairment [see Clinical Pharmacology (12.3) and Dosage and Administration (2.3)]. Fibromyalgia — The recommended dose for Cymbalta is 60 mg admi ...
Ofloxacin
Ofloxacin is a synthetic antibiotic of the fluoroquinolone drug class considered to be a second-generation fluoroquinolone.Ofloxacin was first patented in 1982 (European Patent Daiichi) and received approval from the U.S. Food and Drug Administration (FDA) on December 28, 1990. Ofloxacin is sold under a wide variety of brand names as well as generic drug equivalents, for oral and intravenous administration. Ofloxacin is also available for topical use, as eye drops and ear drops (marketed as Ocuflox and Floxin Otic respectively in the United States and marketed as Optiflox, eylox respectively in Jordan and Saudi Arabia).Ofloxacin is a racemic mixture, which consists of 50% levofloxacin (the biologically active component) and 50% of its “mirror image” or enantiomer dextrofloxacin.Ofloxacin has been associated with adverse drug reactions, such as tendon damage (including spontaneous tendon ruptures) and peripheral neuropathy (which may be irreversible); tendon damage may manifest long after therapy had been completed, and, in severe cases, may result in lifelong disabilities.